https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Fri, 28 Jan 2022 09:23:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/8wieh5xclpm-cyad-101-alloshrink-allogeneic-car-t-cell-therapy-in-mss-mcrc/ Wed, 10 Mar 2021 19:30:20 +0000 http://13.40.107.223/video/8wieh5xclpm-cyad-101-alloshrink-allogeneic-car-t-cell-therapy-in-mss-mcrc/ David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 alloSHRINK trial (NCT03692429) evaluating CYAD-101, a non-gene edited allogeneic CAR-T cell therapy that targets the natural killer group 2D (NKG2D) receptor, in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Preliminary data in 15 patients with MSS mCRC suggests that CYAD-101 therapy may result in improved clinical responses and progression-free survival, although studies are ongoing and further data is required to confirm the benefits in this patient group. This interview took place during the CAR-TCR Summit Europe 2021.

]]>